Upcoming event

Testing the external validity of CARMENA trial comparing sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma

Predicting Functional Outcomes after Partial Nephrectomy

May 2019

Impact of tumor size on cancer specific mortality after local tumor ablation in T1a renal cell carcinoma

Journal of Endourology, April 2019

Clinical utility of the mutational landscape and fragment size of circulating tumor DNA in renal cell carcinoma

March 2019

The role of non-tumour renal biopsy in patients treated with radical nephrectomy

March 2019

Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal call carcinoma patients

March 2019

Identification of a microRNA profile in urine with diagnostic and prognostic value for clear cell renal cell carcinoma

March 2019

Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143)

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study

Should partial nephrectomy be considered “elective” in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy

World Journal of Urology, February 2019

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma

January, 2019

PreviousNext